Subscribe to Search results

At the NETR Haemophilia Working Party, it was suggested that until a positive test for AIDS and/or a vaccine is developed the use of blood products should be avoided. However this did not lead to any change of policy at The Royal London.

Published on:

Dr Colvin clarified that the statement he made that "there is no reason to spurn commercial concentrate" implied that he did not recommend that they don't buy commercial concentrate at all.

Published on:

Dr Colvin stated in his oral evidence "if you had abandoned all surgery except for the most life-saving and the home treatment programme and if you had cut back on dosage...the consequences of the temporary withdrawal of all blood products in the way that Dr Galbraith perfectly understandably recommended was a probable."

Published on:

Dr Colvin reported that there were 41 patients infected with HIV, of which 31 had severe Haemophilia A, 9 had moderate/mild Haemophilia A and 1 had Haemophilia B. He recalled three children who were infected with HIV from their treatment and one partner of a patient who was infected.

Published on:

By the mid 1970s a number of doctors held the view that non-A non-B Hepatitis was a mild or benign disease, which rested centrally on assertion and/or wishful thinking rather than evidence.

Published on:

The publication of "Percutaneous Liver Biopsy and Chronic Liver Disease in Haemophiliacs" in The Lancet meant that clinicians could no longer rely on the absence of overt or acute signs of hepatitis as a reliable indicator that non-A non-B Hepatitis would not develop.

Published on:

Dr Colvin in his evidence described an unwillingness for established clinicians to accept that Factor 8 might be flawed: he called the attitude "wishful thinking".

Published on:

Dr Brian Colvin described in his oral evidence some clinicians' belief that Non-A Non-B Hepatitis was benign as "wishful thinking".

Published on:

Dr Brian Colvin confirmed that, by 1975, the haemophilia treating community was aware that there was at least a possibility of chronic liver disease in haemophilia.

Published on:

Dr Brian Colvin told the Inquiry he treated very small children with cryoprecipitate until the mid 1980s.

Published on:

Dr Brian Colvin told the Inquiry that around 1982-1983 he was using a significant quantity of commercial concentrate in the hospital due to shortfall in NHS concentrate.

Published on:

Dr Winter held that due to the shortage Shortfalls were covered by the use of commercial concentrate, and cryoprecipitate was in limited use only for mild haemophilia or von Willebrand disorder, or occasionally for a child or rarely treated adult.

Published on:

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that patients diagnosed with moderate haemophilia may have also received commercial concentrates

Published on:

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that patients diagnosed with mild haemophilia may have also received commercial concentrates, in instances where DDAVP was proving ineffective.

Published on:

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that while children were prioritised for being treated with NHS products and that prophylactic treatment for children, there was a possibility that children received commercial concentrates too.

Published on:

With regards to treatment taking place at Guy's Hospital and Margate, Dr Winter held that with regards to the treatment of children, the general practice was that children were not given concentrate unless they absolutely needed it.

Published on:

Dr Winter took the post as director at the Haemophilia Centre in Margate in December 1983.

Published on:

Dr Winter held that at the Haemophilia Centre in Margate that around the time of 1983, there was a serious lack of funding.

Published on:

Dr Winter explained that no one approached Tooting hospital to help address the issue of cryoprecipitate supplies.

Published on:

Dr Winter held that both GPs and pharmacists did not have adequate knowledge as to the type or amount of Factor 8 being used for home treatment.

Published on: